Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,770,295

« Back to Dashboard
Patent 6,770,295 protects DETROL LA and is included in one NDA. There has been one Paragraph IV challenge on Detrol LA. There are two tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for DETROL LA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,770,295

Title: Therapeutic formulation for administering tolterodine with controlled release
Abstract:The present invention is drawn to a method of treating an unstable or overactive urinary bladder by treating the patient with tolterodine or a tolterodine-related compound, or pharmaceutically acceptable salt thereof, with a controlled release formulation that maintains a substantially constant serum level of the active moiety or moieties for at least 24 hours. The present invention is further drawn to a formulation for the method.
Inventor(s): Kreilg.ang.rd; Bo (Hillerod, DK), Orup Jacobsen; Lene (Gentofte, DK), Hoeck; Ulla (Hillerod, DK), Kristensen; Helle (Slangerup, DK), Gren; Torkel (Uppsala, SE), Nilvebrant; Lisbeth (Bromma, SE), Ringberg; Anders (Stockholm, SE), Wikberg; Martin (Kullavik, SE), Hallen; Bengt (Sollentuna, SE), Olsson; Birgitta (Stenhamra, SE), Strombom; Jan (Vattholma, SE)
Assignee: Pharmacia AB (Stockholm, SE)
Application Number:09/582,498
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form; Delivery; Compound;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 3rd percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pharmacia And Upjohn
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228-001Dec 22, 2000RXNo6,770,295*PEDFeb 26, 2020Y
Pharmacia And Upjohn
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228-002Dec 22, 2000RXYes6,770,295*PEDFeb 26, 2020Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,770,295

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9802864Aug 27, 1998
Sweden9803871Nov 11, 1998
PCT Information
PCT FiledAugust 26, 1999PCT Application Number:PCT/SE99/01463
PCT Publication Date:March 09, 2000PCT Publication Number: WO00/12069

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.